ABSTRACT Background: Medium-chain triglyceride (MCT) supplements are used by clinicians to treat patients with severe hypertriglyceridemia who are at risk of pancreatitis. However, the potential mechanisms underlying the effects of MCT on triglyceride-rich lipoprotein (TRL) metabolism have not yet been thoroughly examined in humans.
INTRODUCTION
Several lines of evidence have indicated that men and women with insulin resistance (IR) 4 have a 2-to 5-fold higher risk of developing cardiovascular disease than do people without IR (1) (2) (3) (4) . Hypertriglyceridemia associated with IR has been attributed to a combination of increased hepatic production and reduced clearance of VLDL particles (5, 6) . Previous studies have also suggested that IR is associated with an elevated production rate of intestinally derived lipoproteins and contributes to the overall hypertriglyceridemic state in IR individuals (7, 8) . This relation is of significant interest because there is now convincing evidence indicating that elevated concentrations of intestinederived lipoproteins are associated with an increased risk of cardiovascular disease (9) . Chylomicrons are too large to enter the subendothelial space, but once hydrolyzed by the lipoprotein lipase, chylomicron remnants ,700 angstroms are small enough to migrate into the intima and to participate in the development of atherosclerotic lesions (10) . Chylomicron remnants are chemically modified and have been shown to impair normal endothelial function (11) and to accumulate in the subendothelial space in the same way that apolipoprotein (apo) B-100-containing lipoproteins do (12, 13) .
Medium-chain triglycerides (MCTs) are composed of fatty acids with 6-12 carbons and are found primarily in coconut and palm kernel oils (14) . MCTs do not enter the lymphatic and peripheral circulation as chylomicrons but are transported to the liver directly via the portal circulation, where they may affect fuel metabolism (15) . It is well recognized that MCTs have been clinically effective in treating patients with severe hypertriglyceridemia associated with familial hyperchylomicronemia (16, 17) . However, the clinical efficacy of MCTs in patients with other forms of lipoprotein disorders remains controversial. Several studies have shown a significant increase in fasting plasma triglyceride concentrations in subjects consuming $40% of their energy in the form of MCTs (18) (19) (20) , whereas other studies using lower doses of MCTs (20-60 g/d or 12-20% of energy intake) have shown no adverse changes in plasma triglycerides (21) (22) (23) (24) . Asakura et al (23) showed that a test meal containing 25% MCT oil (40 g fat/m significantly reduced postprandial triglyceride concentrations by 36% in patients with primary hypertriglyceridemia. In the present study, we investigated the impact of MCT supplementation on the relations between intestinally derived apo B-48-containing lipoprotein kinetics and the expression of key intestinal genes involved in lipid and lipoprotein metabolism in nondiabetic, IR men. Gene expression studies were conducted by using a human duodenal biopsy model (25) . We hypothesized that MCT supplementation would lead to beneficial changes in the postprandial metabolism of triglyceride-rich lipoproteins (TRLs).
SUBJECTS AND METHODS

Subjects
Twenty-eight nondiabetic, IR men from the Quebec City area were recruited to participate in the study. The IR subjects had to have plasma triglyceride concentrations .1.7 mmol/L, HDLcholesterol concentrations ,1.1 mmol/L, plasma insulin concentrations .90 rmol/L, and a waist circumference .94 cm. Subjects were excluded if they had elevated blood pressure (.140/90 mm Hg), monogenic hyperlipidemia such as familial hypercholesterolemia, plasma triglyceride concentrations .4.5 mmol/L, a recent history of alcohol or drug abuse, diabetes mellitus, or a history of cancer. Furthermore, none of the participants were first-or second-degree relatives. The study consisted of a 1-wk screening period followed by two 4-wk double-blind, crossover intervention periods with corn oil (20 g/d) or MCT oil (20 g/d) supplementation. The supplementation periods occurred in random order, and there was a 4-wk washout period between the 2 phases. The participants were instructed to consume 2 snacks per day, each containing either 10 g of corn oil or 10 g of MCT oil, while maintaining their normal diet and physical activities. The snacks provided to the participants included banana muffins, chocolate cookies, and granola bars. All of these snacks had similar nutritional composition and contained 10 g of MCT oil or corn oil, 250 kcal, 14.5 g of total fat, 27.9 g of carbohydrates, 4.3 g of protein, and 51 mg of cholesterol. Fasting blood samples were obtained at the end of each treatment. Kinetic studies using primed-constant infusion of deuterated leucine were performed in all of the participants, and duodenal biopsies were performed in a subgroup of 16 participants after each phase. The MCT oil was purchased commercially (Nestlé). The research protocol was approved by the Laval University Medical Center Ethical Review Committee, and written informed consent was obtained from each subject. This trial was registered at clinicaltrials. gov as NCT01806142.
Experimental protocol for in vivo stable isotope kinetics
To determine the kinetics of TRL apo B-48 and VLDL apo B-100, the subjects underwent a primed-constant infusion of L- [5,5,5-D 3 ]leucine while they were in a constant fed state. Starting at 0700, the subjects received 30 small, identical cookies every half hour for 15 h, each containing up to 1/30th of their estimated daily food intake based on the Harris-Benedict equation (26) , with 15% of calories from protein, 45% from carbohydrates, and 40% from fat (containing 20 g of corn oil or 20 g of MCT oil depending on the supplementation period), as well as 85 mg of cholesterol/1000 kcal. At 1000, with 2 intravenous lines in place, one for the infusate and one for blood sampling, L- [5,5,5-D 3 ] leucine (10 mmol/kg body weight) was injected as a bolus intravenously and then by continuous infusion (10 mmol $ kg body weight 21 $ h
21
) over a 12-h period. Blood samples (20 mL) were collected at hours 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 11, and 12.
Characterization of plasma lipids and lipoproteins
Twelve-hour fasting venous blood samples were obtained from an antecubital vein before the beginning of the kinetic study. Serum was separated from blood cells by centrifugation at 3000 rpm for 10 min at 48C. Serum cholesterol and triglyceride concentrations were determined with a Roche/Hitachi Modular analyzer (Roche Diagnostics) using Roche Diagnostics reagents. The VLDL (TRL) (d , 1.006 g/mL) fraction was isolated from fresh plasma obtained with Vacutainer tubes containing EDTA (0.1% final concentration) by ultracentrifugation (27) , and HDL cholesterol was measured as previously described (28) . Serum apo B and HDL apo A-I concentrations were measured by using a Behring Nephelometer BN-100 (Behring Diagnostic) with reagents and calibrators (Dade Behring) provided by the manufacturer.
Quantification and isolation of apo B-48 and apo B-100
The apo B concentration in VLDL (TRL) was determined by performing a noncompetitive ELISA using immunopurified polyclonal antibodies (Alerchek Inc) to calculate the respective pool size. The CV for the apo B assay ranged between 6% and 10% depending on the region of the standard curve. Apo B-100 and apo B-48 were then separated by SDS-PAGE according to standardized procedures (29) . Briefly, 100 mL of the TRL fractions was mixed with 50 mL of 3% SDS sample buffer and subjected to electrophoresis in 3-10% linear gradient polyacrylamide slab mini-gels. The gels were stained for 2-3 h in 2.5% Coomassie blue R-250 and destained overnight. On the basis of the assumption that both apo B-100 and apo B-48 have the same chromogenicity, the relative proportions of apo B-100 and apo B-48 were assessed by scanning each gel with laser densitometry (30) . We scanned lipoprotein fractions at 3 different time points to calculate ratios and to estimate the average concentrations of apo B-100 and apo B-48 by using the total apo B concentration.
Isotopic enrichment determinations
The apo B-48 and apo B-100 bands were excised from polyacrylamide gels, and the bands were hydrolyzed in 6 N HCl at 1108C for 24 h (31). Trifluoroacetic acid and trifluoroacetic anhydride (1:1) were used as derivatization reagents for the amino acids before the analyses were performed by using a HewlettPackard 6890/5973 gas chromatograph/mass spectrometer (32) . The isotopic enrichment (%) and tracer:tracee ratios (%) were calculated from the observed ion current ratios (33) . The isotopic enrichment of leucine in the apolipoproteins was expressed as the tracer:tracee ratio (%) by using standardized formulas (33) .
Kinetic analysis
The kinetics of TRL apo B-48 and VLDL apo B-100 were derived by using a multicompartmental model that has been previously described (34) . We assumed that the enrichment of the precursor pool was stable and used the TRL apo B-48 and VLDL apo B-100 plateau of the isotopic enrichment data as the forcing function to drive the appearance of the tracer into apo B-48 and apo B-100 (31) . Under steady state conditions, the fractional catabolic rate is equivalent to the fractional synthetic rate. The apo B production rates (PRs) were determined by using the formula PR (mg $ kg (35) . The plasma volume was estimated at 4.5% of body weight. The SAAM II program (SAAM Institute) was used to fit the model to the observed tracer data.
Intestinal biopsies
Biopsies were obtained from the second portion of the duodenum during gastroduodenoscopy. Six biopsy samples were collected by using multiple-sample, single-use biopsy forceps, immediately flash-frozen in liquid nitrogen, and stored at 2808C before RNA extraction.
Total RNA extraction, RNA quantification, and quantitative real-time polymerase chain reaction
The intestinal biopsy tissue samples were homogenized in 1 mL of Qiazol (Qiagen) and were extracted by using an RNeasy kit (Qiagen). The tissue samples were also treated with an RNasefree DNase set to eliminate any contaminating DNA. Total RNA was then eluted into 100 mL RNase-free H 2 O and stored at 2808C. RNA quantification and quantitative real-time polymerase chain reaction were performed as described (36) .
Power calculations and statistical analysis
This study was designed to provide adequate statistical power to investigate the MCT-induced changes in the kinetics of TRL apo B-48 as the primary outcome. There are currently no data on the effect of MCTs on TRL apo B-48 kinetics in humans.
However, previous data showed that hypertriglyceridemic subjects consuming an MCT-supplemented diet (40 g $ m 22 $ d 21 ) for 2 wk had a 36% reduction in postprandial triglyceride concentrations compared with subjects consuming corn oil (23). Our power analyses suggest that with a final sample size of 28 subjects in this 2-treatment crossover study, the probability is 81% that the study will detect a treatment difference at a onesided 5% significance level, if the true difference in the TRL apo B-48 PR between placebo and MCT supplementation is 35%. This is based on the assumption that the within-patient SD (50%) is greater in magnitude than the main effect per se (35%).
Student's paired t tests were used to compare the effects of MCTs on the fasting lipid-lipoprotein profile, kinetic parameters, and mRNA expression. Mixed models with proper interaction terms were used to assess potential interactions between variables.
Spearman's correlation coefficients were determined to assess the significance of the associations. Differences were considered significant at P # 0.05. All analyses were performed by using JMP statistical software (version 10.0; SAS Institute).
RESULTS
Demographic characteristics and fasting biochemical variables of subjects
Demographic characteristics and fasting biochemical variables of the 28 subjects after a 4-wk intervention with either corn oil or MCT supplementation are shown in Table 1 . The mean (6SD) age of the participants was 37.8 6 10.3 y. No significant differences were observed between the 2 intervention conditions in body weight, waist circumference, or systolic and diastolic blood pressure. MCT supplementation had no significant impact on the fasting lipid/lipoprotein profile compared with corn oil supplementation. 
Kinetics of TRL apo B-48 and VLDL apo B-100
Analyses of the deuterated plasma amino acids and the lipid/ lipoprotein measurements indicated that plasma leucine enrichments, as well as plasma triglyceride and TRL apo B-48 concentrations, remained constant over the course of the infusion (data not shown). Detailed kinetic information obtained by conducting a multicompartmental model analysis is summarized in Figures 1 and 2 . Compared with corn oil supplementation, MCT supplementation had no significant effect on the pool size and kinetics of TRL apo B-48 ( Figure 1 ) or VLDL apo B-100 (Figure 2 ), suggesting that 20 g MCTs/d for 4 wk did not improve postprandial lipemia or apo B-100 metabolism in IR men.
Intestinal mRNA levels
As shown in Table 2 , intestinal SREBP2 gene expression after MCT supplementation was strongly correlated with the mRNA levels of several genes known to be regulated by this nuclear transcription factor: HNF4a (r = 0.51, P , 0.05), HMGCoAR (r = 0.75, P , 0.001), ACAT2 (r = 0.51, P , 0.05), NPC1L1 (r = 0.66, P , 0.05), ACS1 (r = 0.74, P , 0.001), LDLR (r = 0.67, P , 0.05), and PCSK9 (r = 0.60, P , 0.05). HNF4a was also positively associated with HMGCoAR (r = 0.57, P , 0.05), NPC1L1 (r = 0.86, P , 0.0001), and ACS1 (r = 0.66, P , 0.05). The intestinal mRNA expression of FATP4 and FABP2, 2 genes involved in fatty acid metabolism, was also positively correlated (r = 0.71, P , 0.05). However, no significant association was observed between MTP and apo B intestinal mRNA expression. Finally, the PR of TRL apo B-48 was positively correlated with the intestinal mRNA levels of SREBP2 (r = 0.55, P , 0.05), PCSK9 (r = 0.61, P , 0.05), HMGCoAR (r = 0.61, P , 0.05), ACS1 (r = 0.60, P , 0.05), and ACAT2 (r = 0.57, P , 0.05). Similar correlations were observed using the data collected after corn oil supplementation (ie, the control condition). Mixed models with proper interaction terms have shown no evidence of a carryover effect of the MCT oil supplementation (data not shown). Finally, we investigated whether MCT supplementation was associated with variations in the expression of the major genes involved in intestinal lipid and lipoprotein metabolism in individuals with IR. As shown in Table 3 , MCT supplementation had no significant impact on gene expression compared with corn oil. These results suggest that MCT supplementation, at a dose of 20 g/d for 4 wk, does not alter the intestinal expression of key nuclear transcription factors and target genes involved in the metabolism of cholesterol, fatty acids, triglycerides, and lipoproteins.
DISCUSSION
In the present study, MCT supplementation at a dose of 20 g/d for 4 wk had no effect on fasting and postprandial lipemia compared with the control condition (corn oil supplementation). Moreover, MCT supplementation had no significant impact on the mRNA expression of several key intestinal genes involved in lipid and lipoprotein metabolism. These results suggest that short-term consumption of a moderate amount of MCT has no impact on the oversecretion of TRL apo B-48 generally observed in subjects with IR and does not affect the mRNA gene expression at the enterocyte level.
Previous studies have produced conflicting results regarding the effects of MCTs on plasma lipids. In the present study, MCT supplementation had no significant impact on plasma cholesterol and triglyceride concentrations. These results align with previous findings in overweight subjects that showed that MCTs do not increase triglyceride or total and LDL-cholesterol concentrations when they account for 12-20% of the total energy intake (21, 22, 24) . Asakura et al (23) showed that MCT consumption up to a maximum of 24 g/d for 2 wk (compared with corn oil) was not associated with any change in fasting triglyceride concentrations, but that plasma cholesterol concentrations increased. Furthermore, 2 different studies by Nosaka et al (37, 38) showed that there was no significant change in plasma cholesterol and triglyceride concentrations after an MCT intervention for 12 wk and 4 wk, respectively. Woollett et al (39) detected no change in serum concentrations of total, LDL, or HDL cholesterol after 30 d of MCT supplementation in hamsters. These findings contrast with the findings of other studies that found a detrimental effect of MCT on plasma cholesterol and triglyceride concentrations. It is possible that the MCT dose used in the various studies may have confounded the results of earlier studies in which MCTs increased triglyceride or cholesterol concentrations. Indeed, 2 studies in which the subjects consumed 40% of their energy in the form of MCTs at either 100% or 150% of weight-maintenance energy requirements reported significant increases in triglyceride concentrations (42% and 200%, respectively) (19, 20) . Cater et al (18) reported a significant increase in triglyceride concentrations after 3 wk of MCT oil consumption at 43% of energy intake compared with equivalent amounts of palm oil and high-oleic sunflower oil. In 17 healthy young men who replaced part of their habitual dietary fat intake with 70 g MCTs, Tholstrup et al (40) showed that plasma triglycerides increased by 22% and that plasma cholesterol concentratons increased by 11%. In a rat model, Geelen et al (41) showed that MCT oil consumption significantly increased plasma triglyceride concentrations compared with corn oil. The dose-dependent impact of MCTs on plasma lipid profile has been emphasized by Swift et al (20) , who found that subjects who consumed a lower dose of MCTs had no significant increase in fasting triglycerides compared with subjects consuming higher doses. Thus, it may be possible that a high dietary intake of MCTs (.60 g/d or 20% of energy intake) is required to elicit adverse changes in plasma triglyceride and cholesterol concentrations.
MCTs are fairly hydrophilic and thus are rapidly absorbed across the intestinal brush border without the intervention of micellar solubilization (42, 43) . Once absorbed, these compounds are not reesterified and incorporated into the nascent chylomicron; rather, they pass directly into portal circulation, from which they are extracted by the liver. A study by Swift et al (44) in which 93% of dietary fat calories were MCTs showed that the mass of chylomicron triglycerides produced was approximately one-fifth the mass present in subjects who consumed a diet with long-chain triglycerides. The reduced chylomicron formation is the basis for the use of MCTs in the treatment of both type I and type V hyperlipidemia (45) . Only one report has evaluated the effects of MCTs on postprandial lipid concentrations in patients with primary hypertriglyceridemia (23) . In that study, consumption of 24 g MCT oil/d for 4 wk did not change fasting plasma triglyceride concentrations. However, when a test meal containing 25% MCT oil (40 g fat/m 2 body surface area) was administered to the participants, postprandial triglyceride concentrations were significantly reduced over an 8-h period compared with the participants who consumed corn oil. The authors suggested that this reduction in postprandial triglyceride concentrations might be attributable to a reduction in chylomicrons and VLDLcholesterol formation or to the enhancement of the TRL clearance rate. However, these results (from participants in a fed state) contrast with those found in the current study, most likely because of the amount of MCT oil consumed in the test meal. In fact, the same amount of MCT oil (20 g ) over the 15-h period of the kinetic study was consumed, compared with .40 g for the test meal used in the other study in which 24 g MCT/d was used for the 4-wk intervention. Moreover, the fasting plasma triglyceride concentrations in the participants in the Asakura et al study (23) were 3 times those of the participants in the present study, which may partially explain the beneficial effect of MCT oil on postprandial triglycerides that they observed. In contrast, a study that compared serum lipid concentrations in 25 men with a BMI (in kg/m 2 ) $23 who received a single dose of either 10 g of MCTs or long-chain triglycerides showed a significant reduction in postprandial serum and chylomicron triglyceride concentrations (46) . Swift et al (20) also reported that MCT oil significantly decreased postprandial triglycerides after healthy men consumed a test meal containing 40% fat (w44 g). Finally, a previous study showed that the intestinal apo B-48 mass in newborn swine was significantly reduced after they were fed a diet containing 48% MCTs (47) . In the present study, there was no significant change in the TRL apo B-48 pool size in the fed state after MCT supplementation. The production and clearance rates of TRL apo B-48 were not affected by MCT supplementation compared with corn oil supplementation. In addition, the kinetic VLDL apo B-100 variables did not change after MCT supplementation. Therefore, it seems that the dose of MCTs plays an important role on the postprandial response to MCT intake. We also investigated the effect of MCT supplementation on the expression of several key genes involved in lipid and lipoprotein metabolism at the enterocyte level by using intestinal biopsy samples collected at the end of each intervention phase. Consistent with the lack of a change in plasma lipids, MCT supplementation did not produce any significant changes in the intestinal mRNA expression of genes involved in the transport and metabolism of fatty acids and lipoproteins. No previous studies have investigated gene expression at the enterocyte level after MCT supplementation. However, Geelen et al (41) showed that MCT consumption increased the hepatic activities of acetylCoA carboxylase, fatty acid synthase, and diacylglycerol acyltransferase in rats. These changes would be expected to increase hepatic triglyceride production and VLDL secretion. It has been suggested that MCT-rich diets, especially in amounts that exceed caloric needs, might increase de novo fatty acid synthesis and enhance fatty acid elongation activity in the liver (48, 49) , with the consequence of increasing hepatic triglyceride production and VLDL secretion, thus elevating plasma triglyceride concentrations. It has been reported that the activity of 3-hydroxy-3-methylglutaryl-CoA reductase is reduced in rats treated with MCTs (50).
In conclusion, the results of the present study show that 20 g supplemental MCTs/d for 4 wk had no effect on plasma lipids, TRL apo B-48-and apo B-100-containing lipoprotein kinetics, or the intestinal expression of genes involved in lipoprotein and fatty acid metabolism in IR subjects.
